Consumer telehealth · Male fertility & hormones
Posterity Health
Posterity Health is a virtual-first male fertility and hormone clinic with telehealth evaluation and treatment pathways. It is not a provider EHR or patient-engagement inbox.
Strong fit
- Men who need virtual-first fertility evaluation, hormone workups, and coordinated paths into testing or treatment
- Patients comparing clinician-led male reproductive care rather than kit-only sperm freezing alone
- Buyers who want a telehealth center-of-excellence model with named clinical leadership
Weak fit
- People who only want a low-cost at-home freeze kit with no clinician consult
- Couples shopping a full IVF clinic EMR for a fertility practice
- Buyers who need a provider-facing patient-engagement inbox for a medical group
Bottom line
Posterity Health earns a Recommend on our male-fertility consumer-telehealth board as a virtual-first male reproductive and hormone clinic led by CEO Pam Pure with clinical leadership from Dr. Barrett Cowan. Outcomes for patients are access to evaluation and treatment planning, not just a storage kit. Product shape is care delivery plus telehealth operations rather than a pure DTC freeze brand. Implementation for the patient is onboarding into a clinical pathway; diligence still belongs on lab partners and prescribing scope. Funding disclosures include a $13M Series A and earlier rounds, with third-party revenue estimates often under $10M. Score sits under Fellow and Legacy on brand and freeze-product depth, and above CryoChoice and Sppare.me on clinician-led evaluation breadth.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Posterity Health is a virtual-first male fertility and hormone clinic founded in 2021. CEO Pam Pure and chief medical officer Dr. Barrett Cowan lead the company; disclosed equity funding includes a $13M Series A used to expand care and technology.
It is consumer telehealth care delivery, not a provider EHR. Compare Fellow and Legacy when at-home testing and freezing with strong brand reach are the buy, and CryoChoice or Sppare.me when storage kit simplicity matters most.
Score reflects clinician-led breadth on a board still thin on true modality peers.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Fellow | 8.3 | 8.0 |
| Legacy | 8.2 | 8.3 |
| Posterity Health | 7.4 | 7.3 |
| CryoChoice | 7.2 | 6.5 |
| Sppare.me | 6.6 | 7.3 |
Pricing
| Item | Detail |
|---|---|
| Model | Visit and pathway pricing for telehealth evaluations and related services; kit-only competitors publish simpler freeze prices. |
| What usually drives cost | Consult type, labs, medications, and whether freezing or referral pathways are included. |
| What to ask in diligence | Cash price for the initial evaluation pathway you need, including labs and any storage or referral fees. |
| Published pricing | Public list price: pathway quotes via the company site; not a single kit SKU like freeze-only peers. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Posterity Health to function | |
| Clear clinical goal (evaluation, hormones, testing, or freezing) | Vague goals waste consults. |
| Insurance versus cash path understood before booking | Surprise bills erode trust. |
| Partner lab or pharmacy expectations reviewed | Compounded or lab steps vary by pathway. |
| Time window for follow-up labs or storage decisions | Open loops stall care. |
| Identity and consent steps completed before the visit | Incomplete intake blocks clinicians. |
| What will maximize your value | |
| Complete intake and labs before the consult when asked | Missing data burns the visit. |
| Write down questions on fertility goals and timelines | Unfocused visits feel thin. |
| Confirm storage or referral next steps in writing | Verbal plans fade. |
| Track out-of-pocket totals across consults and labs | Pathway cost hides in pieces. |
| Escalate side effects or abnormal results promptly | Silent waiting worsens outcomes. |
| Deal-breakers | |
| You need an in-clinic IVF program as the only acceptable setting. | |
| You refuse clinician evaluation and only want an anonymous kit with no follow-up. | |
| You will not complete identity or consent steps. | |
| You expect a provider EHR purchase for a medical group. | |
| You need guaranteed insurance coverage the company does not offer. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Book & intake | 1-7 days - Account, history, consents. |
| 2 | Consult | Same week to 3 weeks - Clinician visit and plan. |
| 3 | Labs / pathway | 1-4 weeks - Testing, meds, or storage steps. |
| 4 | Follow-up | Ongoing - Results review and next decisions. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.